Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Welcome to the calm before the Covid-19 storm.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Suddenly 2020’s medtech M&A landscape looks very different.